PUBLISHER: Grand View Research | PRODUCT CODE: 2112224
PUBLISHER: Grand View Research | PRODUCT CODE: 2112224
The global hypertrophic and keloid scar treatment market size was valued at USD 763.2 million in 2025 and is projected to grow from USD 842.7 million in 2026 to USD 1,680.2 million by 2033, at a CAGR of 10.4% from 2026 to 2033. Asia Pacific held the largest market share of 46.1% in 2025. The increase in the number of road accidents & burn cases, along with technological advancements and growing awareness regarding the availability of aesthetic surgery, are major factors boosting the industry adoption over the years.
The global increase in the number of road accidents & burn incidence is anticipated to boost the hypertrophic and keloid scar treatment industry. For instance, according to the Association for Safe International Road Travel, approximately 1.35 million people die in road accidents every year. Moreover, as per a similar source, in the U.S., 4.4 million people get seriously injured. The increasing global burden of acne and its long-term secondary effects are key drivers of growth in the hypertrophic and keloid scars industry. In February 2024, a landmark global epidemiology study was published in the Journal of the American Academy of Dermatology (JAAD) by Pierre Fabre Laboratories as part of the ALL-project initiative. This large-scale study surveyed 50,552 adults across 20 countries, representing over 50% of the world's population, making it one of the most comprehensive assessments of acne prevalence and its societal impact.
The study found that global acne prevalence stands at 20.5%, meaning one in five individuals worldwide is affected. Prevalence is highest among adolescents and young adults (16-24 years) at 28.3% and remains high in adults aged 25-39 years at 19.3%. Women are more affected than men (23.6% vs. 17.5%), broadening the long-term consumer base for post-acne scar and pigmentation treatments.
Geographically, the highest prevalence rates were observed in Latin America (23.9%), East Asia (20.2%), Africa (18.5%), and the Middle East (16.1%), while Europe (9.7%) and Australia (10.8%) reported lower rates. Many high-prevalence regions overlap with populations predisposed to PIH and hypertrophic scarring, strengthening demand for targeted topical therapies.
Global Hypertrophic And Keloid Scar Treatment Market Report Segmentation
This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the hypertrophic and keloid scar treatment market report based on scar type, product, end use, and region: